Agarwal R (2006) Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. Am J Physiol Renal Physiol 290: F600–F605
The THIAZOLIDINEDIONE pioglitazone can reduce inflammation in patients with chronic kidney disease secondary to type 2 diabetes mellitus, according to the results of a prospective, single-center trial. The researcher proposes that, through its anti-inflammatory effects, the drug could lessen the high risk of cardiovascular events in this population.
Men with advanced diabetic nephropathy were randomized to receive pioglitazone (n = 21) or the SULPHONYLUREA glipizide (n = 19) for 16 weeks. Levels of biomarkers of inflammation, such as white blood cell count, plasma C-reactive protein and plasma INTERLEUKIN 6 (IL-6), as well of as plasma MATRIX METALLOPROTEINASE 9—an indicator of atherosclerotic plaque stabilization—were significantly reduced after treatment with pioglitazone (P <0.05 for all). The 1,125 cells/µl reduction in white blood cell count and 58% decrease in IL-6 level in the pioglitazone group were significant even when compared with changes in these inflammation biomarkers in the glipizide group (P = 0.009 and P = 0.001, respectively). Levels of plasma TUMOR NECROSIS FACTOR α and markers of oxidative stress (plasma MALONDIALDEHYDE, plasma and urine albumin carbonyl and total protein carbonyl) did not change in response to either therapy.
Pioglitazone is a synthetic PEROXISOME PROLIFERATIVE ACTIVATED RECEPTOR γ agonist that inhibits the expression of proinflammatory genes and reduces monocyte production of inflammatory markers such as IL-6. Subject to confirmation in large trials, pioglitazone could be used together with angiotensin-receptor blockers, statins and aspirin, to reduce cardiovascular event risk in patients with diabetic nephropathy.
Rights and permissions
About this article
Cite this article
Williams, R. Pioglitazone mitigates inflammation in patients with overt diabetic nephropathy. Nat Rev Nephrol 2, 237 (2006). https://doi.org/10.1038/ncpneph0146
Issue Date:
DOI: https://doi.org/10.1038/ncpneph0146